Efficacy of TECAR Therapy in Plantar Fasciitis
NCT07919743, Not applicable, Not yet recruiting, Ankara Etlik City Hospital
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Efficacy of TECAR Therapy in Plantar Fasciitis | ClinicalTrials.gov |
| NCT number | NCT07919743 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 60 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Ankara Etlik City Hospital | ClinicalTrials.gov |
| Conditions | Plantar Fasciitis | ClinicalTrials.gov |
| Interventions | Capacitive and Resistive Energy Transfer (TECAR) therapy, Sham Capacitive and Resistive Energy Transfer (TECAR) Therapy, Standardized Exercise Program | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-10 | ClinicalTrials.gov |
Registered outcomes 7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Morning First-Step Pain (VAS) | Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion. | Morning first-step pain will be assessed using a 10-centimeter (cm) Visual Analog Scale (VAS). Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more severe pain (a worse outcome). Changes in pain intensity will be evaluated from baseline to each follow-up time point. | ClinicalTrials.gov |
| Secondary | General Pain Intensity (VAS) | Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion. | General pain intensity will be assessed using a 10-centimeter (cm) Visual Analog Scale (VAS). Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more severe pain (a worse outcome). | ClinicalTrials.gov |
| Secondary | Pain During Activity (VAS) | Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion. | Pain during activity will be assessed using a 10-centimeter (cm) Visual Analog Scale (VAS). Scores range from 0 (no pain) to 10 (worst imaginable pain); higher scores indicate more severe pain (a worse outcome). | ClinicalTrials.gov |
| Secondary | Foot Function Index (FFI) | Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion. | Foot-related pain, disability, and activity limitation will be evaluated using the Foot Function Index (FFI), which consists of pain, disability, and activity limitation subscales. The total score ranges from 0 to 100; higher scores indicate greater foot-related impairment (a worse outcome). | ClinicalTrials.gov |
| Secondary | Pressure Pain Threshold (PPT) | Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion. | Pressure pain threshold (PPT) will be measured using a pressure algometer at the most painful region of the plantar heel and recorded in kilograms per square centimeter (kg/cm²). Higher values indicate a higher pain threshold, i.e., lower pressure pain sensitivity (a better outcome). | ClinicalTrials.gov |
| Secondary | Plantar Fascia Thickness | Baseline (pre-treatment) and 6 weeks after treatment completion. | Plantar fascia thickness will be measured by ultrasonography at the calcaneal insertion and recorded in millimeters (mm). Greater thickness indicates more pronounced plantar fascia thickening (a worse outcome); a decrease in thickness indicates improvement. | ClinicalTrials.gov |
| Secondary | Health-Related Quality of Life (EuroQol 5-Dimension 5-Level Questionnaire) | Baseline (pre-treatment), 2 weeks (end of treatment), and 6 weeks after treatment completion. | Health-related quality of life will be assessed using the EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire, which covers five dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), each rated on five levels of severity. Responses will be converted into a single EQ-5D-5L index score using the United Kingdom (UK) time trade-off (TTO) value set (Rowen et al., 2026). The index score ranges from -0.567 (worst health state) to 1 (full health), where 0 represents a state equivalent to death and negative values represent states considered worse than death. Higher scores indicate better health-related quality of life (a better outcome). | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)